ClinicalTrials.gg
RecruitingNCT05818189cueingUpdated Dec 17, 2025

Cortical Correlates of Gait in Parkinson's Disease: Impact of Medication and Cueing

An interventional study of Personalized tactile cueing and Fixed tactile cueing in Parkinson Disease, sponsored by Oregon Health and Science University. Recruiting at 1 site in United States. Open to participants aged 45 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-12-17.

Sponsored by Oregon Health and Science University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
45 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 36 studies in Parkinson Disease by Oregon Health and Science University — 4 open to participants now, 4 under way, none of them phase 3. Parkinson Disease · Oregon Health and Science University.

Planned enrollment
7th of 28
60 · median 22
Started
2025
with 1 other
No phase
17 of 36
4 open now
Registered
34th of 36
by date

Among the 36 studies in Parkinson Disease by Oregon Health and Science University, this one is the 7th largest by planned enrollment of the 28 interventional ones that give a count, is one of 2 that started in 2025, is one of 17 with no phase, and was the 34th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

4 of the 36 studies in Parkinson Disease by Oregon Health and Science University are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 45 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Parkinson Disease by Oregon Health and Science University, or all of them as a file.
02

Study summary

The purpose of the study is to determine the effects of a novel, personalized, tactile cueing system on gait automaticity. The researchers hypothesized that step-synchronized tactile cueing will reduce prefrontal cortex activity (improve automaticity) and improve gait variability (as well as gait speed). The researchers predict that improved automaticity with improved gait variability will be associated with increased activation of other than prefrontal cortical areas while walking (i.e., sensory-motor). To determine the effects of cueing, 60 participants with PD from will be randomized into one, of two, cueing interventions: 1) personalized, step-synchronized tactile cueing and 2) tactile cueing at fixed intervals as an active control group. In addition, the researchers will explore the feasibility and potential benefits of independent use of tactile cueing during a week in daily life for a future clinical trial.

This project will characterize the cortical correlates of gait automaticity, the changes in gait automaticity with cueing in people with Parkinson's Disease, and how these changes translate to improvement in gait and turning. The long-term goal is to unravel the mechanisms of impaired gait automaticity in Parkinson's Disease.

Read the detailed description

Cortical correlates of gait automaticity in Parkinson's disease: impact of cueing

A well-recognized hallmark of healthy walking is automaticity, defined as the ability of the nervous system to successfully coordinate movement with minimal use of attention-demanding, executive resources. It has been proposed that many walking abnormalities in people with Parkinson's disease (PD) are characterized by a shift in locomotor control from healthy automaticity to compensatory, executive control. This shift to less automaticity is potentially detrimental to walking performance as executive control strategies are not optimized for locomotor control, place excessive demands on a limited cognitive reserve, and continuously require attention. It has been hypothesized that as gait becomes more variable, as in people with Parkinson's Disease, control of gait is less automatic, i.e., requires more prefrontal cortex involvement. However, as gait variability is not a direct measure of automaticity, it is controversial whether it truly reflects impaired gait automaticity or impaired gait stability (i.e., dynamic balance). The recent development of wireless, functional, near-infrared spectroscopy (fNIRS) of the brain provides more direct, physiological measures of automaticity, such as reduced prefrontal cortex activity. However, the contribution of other cortical areas to the concept of gait automaticity is largely unknown. Here, for the first time, the researchers will use a full cap fNIRS system to monitor cortical activity in multiple brain areas and wearable, inertial sensors to determine how cognitive abilities, levodopa, and cueing influence gait automaticity.

The effects of cognitive dysfunction and interventions on gait in people with Parkinson's Disease are complex. Impaired executive function has been associated with impaired gait and balance in PD, but it is not known if this relationship is due to the inability to compensate for poor basal ganglia control of gait automaticity with increased prefrontal cortex activity while walking. Sensory cueing may increase gait speed and reduce prefrontal activity but unlike levodopa, it may result in reduced gait variability due to enhanced automaticity. The researchers recently developed a novel type of personalized (triggered by the subject's own walking pattern), step-synchronized tactile stimulation on the wrists to improve the quality of gait and turning in people with Parkinson's Disease. The researchers will now compare the effects of cognitive dysfunction, dopaminergic medication, and tactile cueing on the quality of gait and turning and investigate whether improvements reflect changes in prefrontal activity.

This project will characterize the cortical correlates of gait automaticity, the changes in gait automaticity with cueing in people with PD, and how these changes translate to improvement in gait and turning. The long-term goal is to unravel the mechanisms of impaired gait automaticity in Parkinson's Disease.

The purpose of the study is to determine the effects of a novel, personalized, tactile cueing system on gait automaticity. The researchers hypothesized that step-synchronized tactile cueing will reduce prefrontal cortex activity (improve automaticity) and improve gait variability (as well as gait speed). We predict that improved automaticity with improved gait variability will be associated with increased activation of other than prefrontal cortical areas while walking (i.e., sensory-motor). To determine the effects of cueing, 60 participants with PD from will be randomized into one, of two, cueing interventions: 1) personalized, step-synchronized tactile cueing and 2) tactile cueing at fixed intervals as an active control group. A secondary analysis will explore whether the effect of cueing on gait automaticity is influenced by cognitive dysfunction. In addition, we will explore the feasibility and potential benefits of independent use of tactile cueing during a week in daily life for a future clinical trial. We will explore feasibility and efficacy of cueing in daily life comparing data of gait and turning from a week of continuous monitoring without and with using the tactile cueing. In addition, we will test whether any retention on gait and turning is present by adding a third week of continuous monitoring.

03

Conditions studied

  • Parkinson Disease

Browse trials for

Keywords

  • Tactile cueing
  • Gait
  • Turning
  • Cortical activity
04

Who can participate

Ages eligible
45 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of idiopathic Parkinson's Disease from movement disorders neurologist with the United Kingdom Brain Bank criteria of bradykinesia with 1 or more of the following - rest tremor, rigidity, and balance problems not from visual, vestibular, cerebellar or proprioceptive conditions
  • Without musculoskeletal or peripheral or central nervous system disorders (other than PD) that could significantly affect their balance and gait
  • All subjects will be capable of following directions for the protocols and to give .
  • Hoehn \& Yahr Levels II-III.

Exclusion criteria

Exclusion Criteria:

  • Severe dyskinesia that may affect quality of fNIRS.
  • Major musculoskeletal or neurological disorders, structural brain disease, epilepsy, acute illness or health history, other than Parkinson's Disease, significantly affecting gait and turning i.e., peripheral neuropathy with proprioceptive deficits (detected as lack of toe proprioception assessed during the neurological exam at Day 1), musculoskeletal disorders, vestibular problem, head injury, stroke.
  • (MoCA) score \< 21 or dementia that precludes consent to participate or ability to follow testing procedures
  • Inability to stand or walk for 2 minutes without an assistive device.
  • Idiopathic Parkinson's Disease exclusion criteria: Parkinson plus syndromes such as progressive supranuclear palsy, multiple system atrophy, or corticobasal syndrome or implanted electrodes for deep brain stimulation (DBS), possible vascular parkinsonism, current use of dopamine-blocking agents or cholinesterase inhibitor (as may affect Prefrontal cortical activity while walking).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Personalized cueing

    Personalized, step-synchronized tactile cueing, enhancing proprioceptive inputs, in the form of real-time, closed-loop tactile feedback signaling left and right stance times while walking

    Device: Personalized tactile cueing

  • Active comparator
    Fixed cueing

    Tactile cueing at fixed intervals, enhancing proprioceptive inputs, in the form of open-loop tactile feedback (fixed rhythm) signaling left and right stance times while walking

    Device: Fixed tactile cueing

Interventions

  • DevicePersonalized tactile cueing

    We will use as an external cue, a system of tactile cueing with the purpose of enhancing proprioceptive inputs, in the form of real-time(synchronized to the gait heel strike), closed-loop tactile feedback signaling left and right stance times while walking. Also, the participants use the same system cueing in closed-loop feedback during daily life for one week.

    Also known as: personalized

  • DeviceFixed tactile cueing

    We will use as an external cue, a system of tactile cueing with the purpose of enhancing proprioceptive inputs, in the form of real-time, open-loop(fixed rhythm) tactile feedback signaling left and right stance times while walking. Also, the participants use the same system cueing in open-loop feedback during daily life for one week.

    Also known as: fixed

06

What researchers measure

Primary outcomes

  1. Prefrontal cortex activity

    Oxygenated hemoglobin over the prefrontal cortex measures by fNIRS

    Time frame: day 1

  2. Parietal cortex activity

    Oxygenated hemoglobin over the parietal cortex measures by fNIRS

    Time frame: day 1

  3. Stride time variability

    Variability of stride time during 2 minute walking

    Time frame: day 1

  4. Local Dynamic Stability

    Stability during gait is assessed by phase dependent local dynamic stability (LDS) measures of the trunk acceleration while walking

    Time frame: day 1

  5. Turn duration

    Average duration of 360 turning while performing a 1 minute turning in place task

    Time frame: day 1

  6. Turn jerk

    Average turning smoothness while performing a 1 minute turning in place task

    Time frame: day 1

Secondary outcomes

  1. Supplementary motor area cortical activity

    Oxygenated hemoglobin over the SMA cortex measures by fNIRS

    Time frame: day 1

  2. Occipital cortical activity

    Oxygenated hemoglobin over the visual cortex measures by fNIRS

    Time frame: day 1

  3. Gait speed

    Average gait speed during 2 minute walking

    Time frame: day 1

  4. Gait speed variability

    Variability of gait speed during 2 minute walking

    Time frame: day 1

  5. Stride time

    Average stride duration during 2 minute walking

    Time frame: day 1

  6. Stride length

    Average stride length during 2 minute walking

    Time frame: day 1

  7. Stride length variability

    Variability of stride length during 2 minute walking

    Time frame: day 1

  8. Turn duration variability

    Variability of turning duration while performing a 1 minute turning in place task

    Time frame: day 1

  9. Turn jerk variability

    Variability of turning smoothness while performing a 1 minute turning in place task

    Time frame: day 1

  10. Number of steps during turning

    Average number of steps while performing a 1 minute turning in place task

    Time frame: day 1

  11. Number of steps during turning variability

    Variability of number of steps while performing a 1 minute turning in place task

    Time frame: day 1

  12. Turn velocity

    Average turning velocity while performing a 1 minute turning in place task

    Time frame: day 1

  13. Turn velocity variability

    Variability of turning velocity while performing a 1 minute turning in place task

    Time frame: day 1

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Burgos PI, Liu W, Silva-Batista C, Baker-Alcala F, Carlson-Kuhta P, King LA, Horak FB, Chung KA, Lapidus JA, Mancini M. Personalized versus fixed tactile cueing in Parkinson's disease: Protocol for a randomized controlled trial on gait automaticity. PLoS One. 2025 Nov 21;20(11):e0336859. doi: 10.1371/journal.pone.0336859. eCollection 2025. PubMed 41270079 ↗

Individual participant data

Plan to share: Yes — Upon reasonable request, we can share de-identified data related to study outcomes measures.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data would be available 6 months after the end of data collection. Data will be stored in our laboratory data repository and so will be available indefinitely.

Access criteria: Data will not be stored on a public website, however researchers may contact us for access to the data. We will send data electronically via a secure server.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Oct 2027, 32 months after the start.

Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 32 months is above that.

Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 5, 2023
First posted
Apr 18, 2023
StartActual
Jan 15, 2025
Primary completionEst.
Oct 1, 2027
CompletionEst.
Jan 31, 2028
Last update
Dec 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05818189
Responsible party
Martina Mancini (Associate Professor, Oregon Health and Science University) — Principal investigator
First posted
Apr 18, 2023
Start date
Jan 15, 2025
Primary completion
Oct 1, 2027 (estimated)
Completion
Jan 31, 2028 (estimated)
Last update
Dec 17, 2025

Study contacts

Francesa Alcalá, B.S.
Contact
alcalaf@ohsu.edu
503-913-3691
Graham Harker, MPH
Contact
harkerh@ohsu.edu
503-418-2601
Martina Mancini, PhD
principal investigator · Oregon Health and Science University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion